Abstract
Porcine calcitonin in a slow-release gelatin vehicle was given by intramuscular injection to 10 patients—four with primary hyperparathyroidism, four with Paget's disease, and two with carcinoma of the breast and hypercalcaemia. All cases showed a fall in serum calcium with an immediate rise in urine calcium. All except three patients with primary hyperparathyroidism showed a fall in serum phosphorus, but an immediate rise in urine phosphorus occurred in all cases. Urine hydroxyproline output fell in three patients with severe Paget's disease. Urine sodium rose in all cases, but the effects on potassium, magnesium, water, and pH were not appreciably different from results obtained in four control subjects who were given the gelatin vehicle alone.
The data suggest that calcitonin caused a decrease in the tubular resorption of calcium and phosphorus. The hypocalcaemic effect appeared to be due to a decrease in bone resorption in the patients with Paget's disease but in the remaining cases could be accounted for in part or entirely by the rise in urine calcium.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aliapoulios M. A., Goldhaber P., Munson P. L. Thyrocalcitonin inhibition of bone resorption induced by parathyroid hormone in tissue culture. Science. 1966 Jan 21;151(3708):330–331. doi: 10.1126/science.151.3708.330. [DOI] [PubMed] [Google Scholar]
- Ardaillou R., Vuagnat P., Milhaud G., Richet G. Effets de la thyrocalcitonine sur l'excrétion rénale des phosphates, du calcium et des ions H+ chez l'homme. Nephron. 1967;4(5):298–314. doi: 10.1159/000179589. [DOI] [PubMed] [Google Scholar]
- Bijvoet O. L., van der Sluys Veer J., Jansen A. P. Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet. 1968 Apr 27;1(7548):876–881. doi: 10.1016/s0140-6736(68)90236-5. [DOI] [PubMed] [Google Scholar]
- Burkinshaw L., Marshall D. H., Oxby C. B., Spiers F. W., Nordin B. E., Young M. M. Bone turnover model based on a continuously expanding exchangeable calcium pool. Nature. 1969 Apr 12;222(5189):146–148. doi: 10.1038/222146a0. [DOI] [PubMed] [Google Scholar]
- Clark J. D., Kenny A. D. Hog thyrocalcitonin in the dog: urinary calcium, phosphorus, magnesium and sodium responses. Endocrinology. 1969 May;84(5):1199–1205. doi: 10.1210/endo-84-5-1199. [DOI] [PubMed] [Google Scholar]
- Friedman J., Raisz L. G. Thyrocalcitonin: inhibitor of bone resorption in tissue culture. Science. 1965 Dec 10;150(3702):1465–1467. doi: 10.1126/science.150.3702.1465. [DOI] [PubMed] [Google Scholar]
- Milhaud G., Perault A. M., Moukhtar M. S. Etude du mécanisme de l'action hypocalcémiante de la thyrocalcitonine. C R Acad Sci Hebd Seances Acad Sci D. 1965 Jul 19;261(3):813–816. [PubMed] [Google Scholar]
- NORDIN B. E. The effect of intravenous parathyroid extract on urinary pH, bicarbonate and electrolyte excretion. Clin Sci. 1960 May;19:311–319. [PubMed] [Google Scholar]
- Peacock M., Knowles F., Nordin B. E. Effect of calcium administration and deprivation on serum and urine calcium in stone-forming and control subjects. Br Med J. 1968 Jun 22;2(5607):729–731. doi: 10.1136/bmj.2.5607.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peacock M., Robertson W. G., Nordin B. E. Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet. 1969 Feb 22;1(7591):384–386. doi: 10.1016/s0140-6736(69)91353-1. [DOI] [PubMed] [Google Scholar]
- Wallach S., Chausmer A., Mittleman R., Dimich A. In vivo inhibition of bone resorption by thyrocalcitonin. Endocrinology. 1967 Jan;80(1):61–64. doi: 10.1210/endo-80-1-61. [DOI] [PubMed] [Google Scholar]